You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 17, 2024

~ Buy the LUMASON (sulfur hexafluoride lipid-type a microspheres) Drug Profile, 2024 PDF Report in the Report Store ~

LUMASON Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Lumason patents expire, and when can generic versions of Lumason launch?

Lumason is a drug marketed by Bracco and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-seven patent family members in twelve countries.

The generic ingredient in LUMASON is sulfur hexafluoride lipid-type a microspheres. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sulfur hexafluoride lipid-type a microspheres profile page.

DrugPatentWatch® Generic Entry Outlook for Lumason

Lumason was eligible for patent challenges on October 10, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 6, 2038. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

Summary for LUMASON
Drug patent expirations by year for LUMASON
Drug Prices for LUMASON

See drug prices for LUMASON

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LUMASON
Generic Entry Date for LUMASON*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
FOR SUSPENSION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LUMASON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mayo ClinicPhase 2
Thomas Jefferson UniversityPhase 2
Children's Hospital of PhiladelphiaPhase 1

See all LUMASON clinical trials

Pharmacology for LUMASON

US Patents and Regulatory Information for LUMASON

LUMASON is protected by five US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of LUMASON is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting LUMASON

Freeze-dried formulation for gas-filled microvesicles
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Freeze-dried formulation for gas-filled microvesicles
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: USE IN ADULT AND PEDIATRIC PATIENTS WITH SUBOPTIMAL ECHOCARDIOGRAMS TO OPACIFY THE LEFT VENTRICULAR CHAMBER AND TO IMPROVE THE DELINEATION OF THE LEFT VENTRICULAR ENDOCARDIAL BORDER


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: USE IN ULTRASONOGRAPHY OF THE URINARY TRACT IN PEDIATRIC PATIENTS FOR THE EVALUATION OF SUSPECTED OR KNOWN VESICOURETERAL REFLUX


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: USE WITH ULTRASOUND OF THE LIVER IN ADULT AND PEDIATRIC PATIENTS TO CHARACTERIZE FOCAL LIVER LESIONS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bracco LUMASON sulfur hexafluoride lipid-type a microspheres FOR SUSPENSION;INTRAVENOUS 203684-001 Oct 15, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Bracco LUMASON sulfur hexafluoride lipid-type a microspheres FOR SUSPENSION;INTRAVENOUS 203684-001 Oct 15, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Bracco LUMASON sulfur hexafluoride lipid-type a microspheres FOR SUSPENSION;INTRAVENOUS 203684-001 Oct 15, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for LUMASON

When does loss-of-exclusivity occur for LUMASON?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 19298652
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2020022883
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 98380
Estimated Expiration: ⤷  Sign Up

China

Patent: 2165959
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 17777
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 28299
Estimated Expiration: ⤷  Sign Up

Patent: 21529730
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 20012604
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 202010539R
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 2556398
Estimated Expiration: ⤷  Sign Up

Patent: 210029712
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LUMASON around the world.

Country Patent Number Title Estimated Expiration
Australia 2618197 ⤷  Sign Up
Iceland 4089 ⤷  Sign Up
South Korea 960002184 ⤷  Sign Up
Hungary T73251 ⤷  Sign Up
Hungary T74561 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LUMASON

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1556389 16C0004 France ⤷  Sign Up PRODUCT NAME: CEFTOLOZANE,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,PLUS PARTICULIEREMENT UN SEL D'ACIDE SULFURIQUE; REGISTRATION NO/DATE: EU/1/15/1032 20150922
0619743 29/2001 Austria ⤷  Sign Up PRODUCT NAME: SCHWEFELHEXAFLUORID ENTHALTENDE, DURCH PHOSPHORLIPID STABILISIERTE MIKROBLAESCHEN; REGISTRATION NO/DATE: EU/1/01/177/001, EU/1/01/177/002 20010326
1556389 92943 Luxembourg ⤷  Sign Up PRODUCT NAME: CEFTOLOZANE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER UN SEL D'ACIDE SULFURIQUE (ZERBAXA); FIRST REGISTRATION: 20150922
0619743 300061 Netherlands ⤷  Sign Up PRODUCT NAME: ZWAVELHEXAFLUORIDE; REGISTRATION NO/DATE: EU/1/01/177/001 20010326
0619743 01C0036 France ⤷  Sign Up PRODUCT NAME: SULPHUR HEXAFLUORIDE; REGISTRATION NO/DATE: EU/1/01/177/001 20010326
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.